

6. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. *Journal of the American Academy of Dermatology*. 2004;50(5):722-733.
7. Roldán-Marín R, Toussaint-Caire S. Imiquimod 5% as adjuvant therapy for incompletely excised infiltrative nodular basal cell carcinoma and dermoscopy to monitor treatment response. *Dermatology and Therapy*. 2015;5(4):265-272.
8. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (SBCC) predicts imiquimod efficacy: A proposal for a thickness-based definition of SBCC. *British Journal of Dermatology*. 2013;169(3):549-554.
9. Roozeboom MH, Arits AHM, Nelemans PJ, et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: A systematic review and meta-analysis of randomized and nonrandomized trials. *British Journal of Dermatology*. 2012;167(4):733-756.
10. Sharquie KE, Noaimi AA. Basal cell carcinoma: Topical therapy versus surgical treatment. *Journal of the Saudi Society of Dermatology & Dermatologic Surgery*. 2012;16(2):41-51.
11. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. *Journal of the American Academy of Dermatology*. 2018;78(3):540-559.
12. van Delft LCJ, Nelemans PJ, Kessels JPHM, et al. Long-term efficacy of photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus conventional two-stage topical methyl aminolevulinate for superficial basal-cell carcinoma. *Dermatology*. 2022;238(6):1044-1049.
13. Ceilley RJ, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. *International Journal of Dermatology*. 2006;45(5):489-498.
14. Habashy S, Jafri A, Osman HO, et al. Hedgehog pathway inhibitors: Clinical implications and resistance in the treatment of basal cell carcinoma. *Cureus*. 2021;13(3):13859.
15. Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. *International Journal of Molecular Sciences*. 2022;23(3):1733.
16. Gambini D, Passoni E, Nazzaro G, et al. Basal cell carcinoma and hedgehog pathway inhibitors: Focus on immune response. *Frontiers in Medicine*. 2022;9.
17. Yin VT, Sniegowski M, Esmaeli B. Indications and limitations of vismodegib for basal cell carcinoma. *JAMA Ophthalmology*. 2014;132(7):905-906.
18. Cozzani R, Aguila R, Carrizo M, et al. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina. *International Journal of Dermatology*. 2020;59(5):627-632.
19. ClinicalTrials.gov. Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients – Full Text View. [cited 2023 Mar 1]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02762084>.
20. ClinicalTrials.gov. Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas – Full Text View. [cited 2023 Mar 1]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02828111>.
21. Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. *Advances in Therapy*. 2022;39(3):1164-1178.
22. Verkouteren BJA, Sinx KAE, Reinders MGHC, et al. Update on hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma. *Acta Dermato-Venereologica*. 2022;102:980.
23. Zeng L, Gowda BH, Ahmed MG, et al. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. *Molecular Cancer*. 2023;22(1).
24. Souto EB, Macedo AS, Dias-Ferreira J, et al. Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (apis). *International Journal of Molecular Sciences*. 2021;22(18):9743.
25. Zielińska A, Szalata M, Gorczyński A, et al. Cancer nanopharmaceuticals: Physicochemical characterization and in vitro/in vivo applications. *Cancers*. 2021;13(8):1896.
26. Calienni MN, Febres-Molina C, Llovera RE, et al. Nanof ormulation for potential topical delivery of Vismodegib in skin cancer treatment. *International Journal of Pharmaceutics*. 2019;565:108-122.
27. Morton CA, Dominicus R, Radny P, et al. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy. *British Journal of Dermatology*. 2018;179(2):309-319.
28. Mohammadpour R, Dobrovolskaia MA, Cheney DL, et al. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for Delivery Applications. *Advanced Drug Delivery Reviews*. 2019;144:112-132.
29. Tang W, Fan W, Lau J, et al. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. *Chemical Society Reviews*. 2019;48(11):2967-3014.
30. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (SBCC) predicts imiquimod efficacy: A proposal for a thickness-based definition of SBCC. *British Journal of Dermatology*. 2013;169(3):549-554.
31. Łasińska I, Zielińska A, Mackiewicz J, et al. Basal cell carcinoma: Pathology, current clinical treatment, and potential use of lipid nanoparticles. *Cancers*. 2022;14(11):2778.
32. Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. *Indian Dermatology Online Journal*. 2013;4(1):12.